XMAG's expense ratio is lowered by lending shares of heavily shorted small-caps. The Magnificent Seven exclusion funds this edge. Here is the mechanism.
The XMAG exchange-traded fund, which tracks an equal-weight version of the S&P 500, has a structural advantage that most investors overlook. The fund's expense ratio is effectively lower than the stated figure because securities-lending revenue from heavily shorted small-cap components flows back to offset operating costs. The excluded mega-caps – the Magnificent Seven – rarely generate lending income. They are, in effect, subsidizing the equal-weight strategy.
At first glance, XMAG offers a simple proposition. It holds the same 500 stocks as the cap-weighted S&P 500 but weights them equally. A $10 billion company gets the same allocation as a $3 trillion one. The naive interpretation is that this is a bet on smaller large-caps outperforming.
The better market read focuses on the funding mechanism. XMAG lends out shares of the most heavily shorted names in the index. Those names tend to be the smaller, less liquid components of the S&P 500 – the very stocks that get a larger weight in an equal-weight fund than in a cap-weighted one. Securities lending revenue from these hard-to-borrow names reduces the fund's effective expense ratio. The result is that XMAG's cost to hold is lower than what a purely passive equal-weight product would otherwise require.
The S&P 500's 6.5% May Gain Hides Narrow Tech Leadership context matters here. When a handful of mega-caps dominate index returns, short interest concentrates in the rest of the index. That is precisely when XMAG's lending revenue peaks.
The Magnificent Seven stocks – Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla – dominate the cap-weighted S&P 500. They are also rarely shorted at levels that generate meaningful lending income. Their size and liquidity mean borrow fees are low. XMAG excludes these stocks from the securities-lending revenue pool because they are not in the fund's heavy-lending set.
Instead, the fund's lending revenue comes from the other 493 names. When short interest concentrates in those names – during sector rotation or market stress – the revenue stream widens. The effective cost of XMAG can fall well below the stated expense ratio. This narrows the fee gap that often pushes investors toward cap-weighted products.
A sustained rally in mega-cap tech stocks would reduce short interest in the smaller names, cutting lending revenue and raising XMAG's effective cost. Conversely, a broadening of the market where capital flows into smaller S&P 500 components would increase both the fund's relative performance and its securities lending income.
Two metrics to watch:
XMAG's structural edge is not a standalone reason to buy or sell the fund. It is a reason to recalculate the cost of equal-weight exposure versus cap-weight exposure. If the gap between stated and effective expense ratio widens, the fund becomes a more efficient vehicle for a diversified large-cap allocation. If it narrows, the cost advantage that separates XMAG from other equal-weight products will shrink. The next quarterly report will provide the data.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.